新辅助化疗TAC方案对乳腺癌保乳手术患者临床疗效、肿瘤标志物及预后的影响

Effects of Primary Chemotherapy TAC Scheme on Clinical Efficacy,Tumor Markers and Prognosis of Breast Cancer Patients Undergoing Breast Conserving Surgery

目的:研究新辅助化疗(primary chemotherapy,PcT)TAC(环磷酰胺+表柔比星+多西他赛)方案治疗乳腺癌保乳手术患者的临床疗效.方法:回顾性分析2019 年1 月至2020 年1 月本院收治的198 例乳腺癌(BC)患者临床资料.根据治疗方式不同将这些患者分为观察组(n=103,PcT TAC 方案结合保乳术治疗)和对照组(n=95,仅保乳术治疗),对比两组治疗效果.结果:观察组疾病缓解率(74.76%)显著高于对照组(52.63%);治疗后观察组患者的肿瘤标志物CEA、CA125、CA153 蛋白水平及Ki-67 mRNA 水平显著低于对照组,差异有统计学意义(P<0.05);观察组复发率(1.94%)显著低于对照组(16.84%),差异有统计学意义(P<0.05).结论:新辅助化疗TAC 方案更有利于提高乳腺癌保乳手术患者的疾病缓解率,可显著降低CEA、CA125、CA153 及Ki-67mRNA 水平,复发率更低.

Objective:To study the clinical efficacy of primary chemotherapy(PcT) TAC(Cyclophosphamide+epirubicin+docetaxel)regimen in the treatment of breast cancer(BC)patients undergoing breast conserving surgery.Methods:The clinical data of 198 BC patients admited to our hospital from January 2019 to January 2020 were retrospectively analyzed,and according to diferent treatment methods,the patients were divided into an observation group(n=103,PcT TAC combined with breast-conserving therapy)and a control group(n=95,breast-conserving therapy only).And the treatment effects were compared between the two groups.Results:The remission rate of disease in the observation group(74.76%)was significantly higher than that in the control group(52.63%).After treatment,levels of tumor marker CEA,CA125,CA153 proteins and Ki-67 mRNA in the observation group were significantly lower than those in the control group(P<0.05).And the recurrence rate of the observation group(1.94%)was significantly lower than that of the control group(16.84%)(P<0.05).Conclusion:TAC regimen of neoadjuvant chemotherapy is more beneficial to improve the remission rate of breast cancer patients after breast conserving surgery,and can significantly reduce CEA,CA125,CA153 and Ki-67 mRNA levels,which has lower recurrence rate and better application.